Real-time status, AI confidence scores, and what the Oracle sees next for psilocybin therapy FDA review.
Last updated: 2026-05-25 · View all Oracle predictions →
The psilocybin FDA approval question is no longer hypothetical. After years of breakthrough-therapy designations, Phase 2 data, and cautious optimism from regulators, 2026 has emerged as the most consequential year in psychedelic medicine history. Compass Pathways has completed two successful Phase 3 trials for COMP360 — its synthetic psilocybin compound for treatment-resistant depression — and the FDA has responded by issuing Priority Review Vouchers for psilocybin for the first time.
This tracker synthesizes the current psilocybin approval status across all major regulatory vectors: the Compass Pathways COMP360 NDA track, DEA rescheduling, and the broader political environment shaped by a White House executive order signed in April 2026. The Oracle AI swarm assigns confidence scores to each milestone using multi-model probabilistic analysis updated daily.
Whether you're a patient, clinician, investor, or researcher following the psychedelic FDA timeline, this page gives you a single authoritative source — no paywalls, no spin, just probability-weighted forecasts grounded in regulatory precedent and real-time signal.
Four parallel tracks define the psilocybin FDA approval landscape in 2026. The Oracle monitors each one in real time.
From Phase 3 precedent to NDA submission — every milestone on the psychedelic FDA timeline, with Oracle probability scores for what comes next.
Confidence-scored predictions from the OOTWOracle AI swarm. Each score reflects multi-model consensus across regulatory precedent, trial data, and political signal. See all active predictions →
Why 2026 is different from previous years. The psilocybin approval conversation has been ongoing since Johns Hopkins received breakthrough therapy designation for psilocybin in depression in 2018. What makes 2026 categorically different is the convergence of three forces that have never aligned before: two Phase 3 trials with positive data from the same sponsor, a formal FDA priority review mechanism specifically applied to psilocybin, and a political environment — for the first time in decades — actively accelerating rather than obstructing the pathway.
The COMP360 advantage over MDMA. The failure of MDMA-assisted therapy in 2024 was instructive rather than discouraging. FDA's Complete Response Letter cited concerns about functional unblinding (patients knew when they were on MDMA), trial design limitations, and manufacturing issues. COMP360's profile addresses all three: psilocybin's single-session administration model is more controllable, Compass has invested heavily in CMC documentation, and their clinical trial design incorporated blinding controls from the outset. The Compass Pathways FDA track benefits directly from the MDMA regulatory education.
What REMS means for patients. A Risk Evaluation and Mitigation Strategy — which the Oracle assigns 88% probability of being required — would mean that even after FDA approval, psilocybin therapy would not be available at a corner pharmacy. Certified treatment centers, trained therapists, and medical supervision would be required. This is analogous to the esketamine (Spravato) REMS model, where the drug is only administered in certified healthcare settings. For patients, this means access but not convenience — a significant shift nonetheless from the current Schedule I classification.
State-level access vs. federal approval. Colorado and Oregon have both enacted state frameworks permitting supervised psilocybin services independent of federal scheduling. These programs operate under state law, not FDA approval, and do not involve pharmaceutical-grade synthetic psilocybin. FDA approval of COMP360 would create a parallel, insurance-eligible pathway — a meaningful but separate development from the existing state access programs.
For continuously updated forecasts on the full range of psychedelic medicine predictions, including competing therapies, legislative developments, and international approvals, visit the main OOTWOracle predictions hub.
Full FDA approval in 2026 is possible but not certain. Compass Pathways has not yet filed its NDA for COMP360, making 2026 the likely submission year rather than approval year. The Oracle AI swarm assigns 78% confidence that an approval decision arrives by Q4 2026 or early Q1 2027, contingent on an NDA submission in Q3 2026 and a standard 6-month Priority Review clock. The most likely approval scenario resolves in Q1 2027.
Compass Pathways has completed two consecutive successful Phase 3 trials for COMP360 in treatment-resistant depression — COMP005 (June 2025) and COMP006 (February 2026). The company is currently in pre-NDA meetings with the FDA and has received a Priority Review Voucher issued in April 2026. An NDA submission is expected in Q3 2026, which would trigger the FDA's 6-month Priority Review clock. This represents the most advanced psilocybin approval status in regulatory history.
DEA rescheduling of psilocybin from Schedule I is legally contingent on an FDA approval — it is not a standalone action the DEA can take independently on current timelines. Once the FDA approves a psilocybin-based drug, the DEA is obligated to initiate rescheduling proceedings. The Oracle projects DEA rescheduling from Schedule I completing in 2027 at the earliest, likely to Schedule II (similar to other controlled substances with accepted medical use), if an FDA approval lands in late 2026 or early 2027.
COMP360 is Compass Pathways' proprietary synthetic psilocybin compound being developed as a treatment for treatment-resistant depression (TRD) — major depression that hasn't responded to at least two adequate antidepressant treatments. It is administered as a single 25mg oral dose in a controlled therapeutic setting with professional psychological support. COMP360 holds FDA Breakthrough Therapy Designation and Fast Track Designation, and is the frontrunner in the psilocybin FDA approval race as of 2026.
No classic psychedelic has received full FDA approval as of May 2026. The FDA rejected MAPS' MDMA-assisted therapy (midomafetamine) for PTSD in August 2024, citing manufacturing concerns and trial design limitations. However, ketamine (a dissociative, not a classic psychedelic) has been used off-label for depression since 2000, and esketamine (Spravato) was FDA-approved in 2019 for treatment-resistant depression. Psilocybin therapy via COMP360 is the leading candidate for the first classic psychedelic to receive full FDA approval.
The FDA uses several mechanisms to accelerate review of promising drugs for serious conditions. Breakthrough Therapy Designation (BTD) is the most significant — it provides intensive FDA guidance and rolling review for drugs showing early clinical evidence of substantial improvement over existing therapies. Both COMP360 and several other psychedelic compounds hold BTD. In April 2026, the FDA issued Priority Review Vouchers for psilocybin, a novel development that can cut the standard 10-month review clock to approximately 6 months. The Trump Executive Order also directs the FDA to develop a formal psychedelic medicines review pathway.
The Oracle monitors FDA dockets, DEA filings, clinical trial registries, and political signals 24/7. Subscribe to Oracle Signal and receive probability updates the moment anything changes in the psilocybin FDA timeline.
No spam. Unsubscribe anytime. Join 12,000+ researchers, clinicians, and investors tracking the psychedelic FDA timeline.